[Form 4] PRECISION BIOSCIENCES INC Insider Trading Activity

Rhea-AI Filing Summary

Precision BioSciences director Melinda Brown made an open-market purchase of company stock on 09/22/2025. She acquired 1,400 shares of Common Stock at a price of $4.89 per share, increasing her direct beneficial ownership to 21,965 shares following the transaction. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Brown on 09/24/2025. The filing identifies Ms. Brown as a director and indicates this Form 4 was filed by one reporting person. No derivative transactions or other securities classes are reported on this form.

Positive

• Director purchase disclosed: Melinda Brown acquired 1,400 shares on 09/22/2025, demonstrating insider buying activity.
• Clear pricing: Transaction price is stated as $4.89 per share.
• Post-transaction ownership provided: Direct beneficial ownership is reported as 21,965 shares following the purchase.

Negative

• None.

Insights

Financial Analyst

TL;DR: A director purchased 1,400 shares at $4.89, modestly increasing direct ownership to 21,965 shares.

The filing documents a single open-market purchase by a company director, showing a straightforward purchase price and post-transaction share count. This is a routine disclosure under Section 16 and provides transparency on insider activity. The purchase size and disclosed holdings are explicit in the form; no derivatives or additional transactions were reported. The filing does not include additional context such as grant details or a trading plan.

Corporate Governance Expert

TL;DR: Routine insider purchase reported correctly; signature executed by attorney-in-fact.

The Form 4 identifies Melinda Brown as a director and reports an acquisition of 1,400 common shares at $4.89, with the form signed by an attorney-in-fact. The disclosure meets the Section 16 reporting requirement by showing the transaction date and resulting beneficial ownership. There are no amendments, joint filings, or derivative holdings disclosed on this submission.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brown Melinda

(Last) (First) (Middle)

C/O PRECISION BIOSCIENCES, INC.

302 E. PETTIGREW STREET, SUITE A-100

(Street)

DURHAM NC 27701

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PRECISION BIOSCIENCES INC [ DTIL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/22/2025		P		1,400	A	$4.89	21,965	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Dario Scimeca, Attorney-in-fact for Melinda Brown	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Melinda Brown report on Form 4 for DTIL?

The Form 4 reports that Melinda Brown purchased 1,400 shares of Precision BioSciences (DTIL) on 09/22/2025.

At what price did the director buy DTIL shares?

The reported purchase price was $4.89 per share.

How many DTIL shares does Melinda Brown beneficially own after the reported transaction?

Following the reported purchase, Melinda Brown beneficially owns 21,965 shares directly.

Was the Form 4 filed jointly or by a single reporting person?

The form indicates it was filed by one reporting person (not jointly).

Who signed the Form 4 filing for Melinda Brown?

The Form 4 was signed by Dario Scimeca, Attorney-in-fact for Melinda Brown on 09/24/2025.